However, to date, only a limited set of GPCR-targeted peptidic theranostics (e.g., analogs of somatostatin, vasointestinal peptide, and bombesin/gastrin-releasing peptides) have been developed for detecting and treating PCa, and their clinical applicability is currently under investigation [12,13,14,15,16,17]. Here, GRP is linked to posterior cortical atrophy.